One completed clinical trial (NCT04640324) uses nutraceutical treatment where participants with NAFLD carrying patatin-like phospholipase domain-containing protein 3 (PNPLA3)-rs738409, transmembrane 6 superfamily member 2 (TM6SF2)-rs58542926, or membrane-bound O-acetyltransferase 7 (MBOAT7)-rs641738 genetic variants consume 303 mg of silybin-phospholipids complex, 10 μg of vitamin D, and 15 mg vitamin E orally twice a day for six months. Here, TM6SF2 is linked to metabolic dysfunction-associated steatotic liver disease.